Tyra announces initial data from Phase II SURF302 trial of dabogratinib

Phase 2dabogratinibNeutral

AI Analysis

Summary

Tyra Biosciences announced initial data from its Phase II SURF302 trial evaluating dabogratinib in FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer patients. No specific efficacy or safety data details were provided in the announcement.

Clinical Trial Data

Phase

Importance:5/10

Sentiment:

0.00

Phase 2bladder cancerFGFR3oral therapyNMIBC

Related Companies

$TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on September 10, 2026 8:15 AM

Read Original